Immunome, Inc. (NASDAQ:IMNM – Get Rating) – Equities researchers at Cantor Fitzgerald upped their FY2022 EPS estimates for shares of Immunome in a note issued to investors on Tuesday, November 22nd. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings per share of ($3.18) for the year, up from their prior forecast of ($3.25). The consensus estimate for Immunome’s current full-year earnings is ($3.11) per share. Cantor Fitzgerald also issued estimates for Immunome’s FY2023 earnings at ($1.64) EPS.
Immunome Stock Performance
Shares of IMNM stock opened at $3.53 on Thursday. The stock’s fifty day moving average is $4.35 and its two-hundred day moving average is $4.15. The firm has a market capitalization of $42.76 million, a P/E ratio of -1.13 and a beta of 0.46. Immunome has a fifty-two week low of $2.09 and a fifty-two week high of $19.65.
Institutional Trading of Immunome
Immunome Company Profile
Immunome, Inc, a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.
- Get a free copy of the StockNews.com research report on Immunome (IMNM)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.